Metastatic Melanoma Diagnostic Market, Global Outlook and Forecast 2023-2029

Report ID: MMG171000 | Category: Service & Software | Pages: 61 | Format: PDF | Published Date: August 16,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Melanoma is one of the serious types of skin cancers that develops from pigment-containing cells called as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are most common on the back. Moles, brown spots and growths on the skin are found to be the symptoms associated with the disease. When it spreads to other places in body, it's called metastatic, or advanced. Although in many cases metastatic melanoma can’t be cured, treatments and support can help people live longer and better. Doctors have therapies that have greatly increased survival rates. And researchers are working to find new medications that can do even more.
This report aims to provide a comprehensive presentation of the global market for Metastatic Melanoma Diagnostic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metastatic Melanoma Diagnostic. This report contains market size and forecasts of Metastatic Melanoma Diagnostic in global, including the following market information:
Global Metastatic Melanoma Diagnostic Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Metastatic Melanoma Diagnostic market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
BRAF Mutation Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Metastatic Melanoma Diagnostic include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, Cancer Genetics, Castle Biosciences, NeoGenomics, Dermtech and Sysmex Inostics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metastatic Melanoma Diagnostic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metastatic Melanoma Diagnostic Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, by Type, 2022 (%)
    BRAF Mutation
    Circulating Tumor Cells (CTCs)
    Immunohistochemistry
    Others
Global Metastatic Melanoma Diagnostic Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, by Application, 2022 (%)
    Pathology Laboratories
    Hospitals
    Cancer Research Centres
    Others
Global Metastatic Melanoma Diagnostic Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Metastatic Melanoma Diagnostic Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metastatic Melanoma Diagnostic revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Metastatic Melanoma Diagnostic revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Myriad Genetics
    Abbott Laboratories
    Foundation Medicine
    Pathway Genomics Corporation
    Cancer Genetics
    Castle Biosciences
    NeoGenomics
    Dermtech
    Sysmex Inostics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Metastatic Melanoma Diagnostic, market overview.
Chapter 2: Global Metastatic Melanoma Diagnostic market size in revenue.
Chapter 3: Detailed analysis of Metastatic Melanoma Diagnostic company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metastatic Melanoma Diagnostic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Metastatic Melanoma Diagnostic Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Metastatic Melanoma Diagnostic Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Metastatic Melanoma Diagnostic Overall Market Size
    2.1 Global Metastatic Melanoma Diagnostic Market Size: 2022 VS 2029
    2.2 Global Metastatic Melanoma Diagnostic Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Metastatic Melanoma Diagnostic Players in Global Market
    3.2 Top Global Metastatic Melanoma Diagnostic Companies Ranked by Revenue
    3.3 Global Metastatic Melanoma Diagnostic Revenue by Companies
    3.4 Top 3 and Top 5 Metastatic Melanoma Diagnostic Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Metastatic Melanoma Diagnostic Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Metastatic Melanoma Diagnostic Players in Global Market
        3.6.1 List of Global Tier 1 Metastatic Melanoma Diagnostic Companies
        3.6.2 List of Global Tier 2 and Tier 3 Metastatic Melanoma Diagnostic Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Metastatic Melanoma Diagnostic Market Size Markets, 2022 & 2029
        4.1.2 BRAF Mutation
        4.1.3 Circulating Tumor Cells (CTCs)
        4.1.4 Immunohistochemistry
        4.1.5 Others
    4.2 By Type - Global Metastatic Melanoma Diagnostic Revenue & Forecasts
        4.2.1 By Type - Global Metastatic Melanoma Diagnostic Revenue, 2018-2023
        4.2.2 By Type - Global Metastatic Melanoma Diagnostic Revenue, 2024-2029
        4.2.3 By Type - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Metastatic Melanoma Diagnostic Market Size, 2022 & 2029
        5.1.2 Pathology Laboratories
        5.1.3 Hospitals
        5.1.4 Cancer Research Centres
        5.1.5 Others
    5.2 By Application - Global Metastatic Melanoma Diagnostic Revenue & Forecasts
        5.2.1 By Application - Global Metastatic Melanoma Diagnostic Revenue, 2018-2023
        5.2.2 By Application - Global Metastatic Melanoma Diagnostic Revenue, 2024-2029
        5.2.3 By Application - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Metastatic Melanoma Diagnostic Market Size, 2022 & 2029
    6.2 By Region - Global Metastatic Melanoma Diagnostic Revenue & Forecasts
        6.2.1 By Region - Global Metastatic Melanoma Diagnostic Revenue, 2018-2023
        6.2.2 By Region - Global Metastatic Melanoma Diagnostic Revenue, 2024-2029
        6.2.3 By Region - Global Metastatic Melanoma Diagnostic Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Metastatic Melanoma Diagnostic Revenue, 2018-2029
        6.3.2 US Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.3.3 Canada Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.3.4 Mexico Metastatic Melanoma Diagnostic Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Metastatic Melanoma Diagnostic Revenue, 2018-2029
        6.4.2 Germany Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.4.3 France Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.4.4 U.K. Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.4.5 Italy Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.4.6 Russia Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.4.7 Nordic Countries Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.4.8 Benelux Metastatic Melanoma Diagnostic Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Metastatic Melanoma Diagnostic Revenue, 2018-2029
        6.5.2 China Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.5.3 Japan Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.5.4 South Korea Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.5.5 Southeast Asia Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.5.6 India Metastatic Melanoma Diagnostic Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Metastatic Melanoma Diagnostic Revenue, 2018-2029
        6.6.2 Brazil Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.6.3 Argentina Metastatic Melanoma Diagnostic Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Metastatic Melanoma Diagnostic Revenue, 2018-2029
        6.7.2 Turkey Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.7.3 Israel Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.7.4 Saudi Arabia Metastatic Melanoma Diagnostic Market Size, 2018-2029
        6.7.5 UAE Metastatic Melanoma Diagnostic Market Size, 2018-2029
7 Metastatic Melanoma Diagnostic Companies Profiles
    7.1 Myriad Genetics
        7.1.1 Myriad Genetics Company Summary
        7.1.2 Myriad Genetics Business Overview
        7.1.3 Myriad Genetics Metastatic Melanoma Diagnostic Major Product Offerings
        7.1.4 Myriad Genetics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.1.5 Myriad Genetics Key News & Latest Developments
    7.2 Abbott Laboratories
        7.2.1 Abbott Laboratories Company Summary
        7.2.2 Abbott Laboratories Business Overview
        7.2.3 Abbott Laboratories Metastatic Melanoma Diagnostic Major Product Offerings
        7.2.4 Abbott Laboratories Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.2.5 Abbott Laboratories Key News & Latest Developments
    7.3 Foundation Medicine
        7.3.1 Foundation Medicine Company Summary
        7.3.2 Foundation Medicine Business Overview
        7.3.3 Foundation Medicine Metastatic Melanoma Diagnostic Major Product Offerings
        7.3.4 Foundation Medicine Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.3.5 Foundation Medicine Key News & Latest Developments
    7.4 Pathway Genomics Corporation
        7.4.1 Pathway Genomics Corporation Company Summary
        7.4.2 Pathway Genomics Corporation Business Overview
        7.4.3 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Major Product Offerings
        7.4.4 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.4.5 Pathway Genomics Corporation Key News & Latest Developments
    7.5 Cancer Genetics
        7.5.1 Cancer Genetics Company Summary
        7.5.2 Cancer Genetics Business Overview
        7.5.3 Cancer Genetics Metastatic Melanoma Diagnostic Major Product Offerings
        7.5.4 Cancer Genetics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.5.5 Cancer Genetics Key News & Latest Developments
    7.6 Castle Biosciences
        7.6.1 Castle Biosciences Company Summary
        7.6.2 Castle Biosciences Business Overview
        7.6.3 Castle Biosciences Metastatic Melanoma Diagnostic Major Product Offerings
        7.6.4 Castle Biosciences Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.6.5 Castle Biosciences Key News & Latest Developments
    7.7 NeoGenomics
        7.7.1 NeoGenomics Company Summary
        7.7.2 NeoGenomics Business Overview
        7.7.3 NeoGenomics Metastatic Melanoma Diagnostic Major Product Offerings
        7.7.4 NeoGenomics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.7.5 NeoGenomics Key News & Latest Developments
    7.8 Dermtech
        7.8.1 Dermtech Company Summary
        7.8.2 Dermtech Business Overview
        7.8.3 Dermtech Metastatic Melanoma Diagnostic Major Product Offerings
        7.8.4 Dermtech Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.8.5 Dermtech Key News & Latest Developments
    7.9 Sysmex Inostics
        7.9.1 Sysmex Inostics Company Summary
        7.9.2 Sysmex Inostics Business Overview
        7.9.3 Sysmex Inostics Metastatic Melanoma Diagnostic Major Product Offerings
        7.9.4 Sysmex Inostics Metastatic Melanoma Diagnostic Revenue in Global Market (2018-2023)
        7.9.5 Sysmex Inostics Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Metastatic Melanoma Diagnostic Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?